Iksuda Therapeutics Receives FDA IND Clearance for IKS014
IKS014 is currently being investigated in an open-label phase 1 dose-escalation study (https://clinicaltrials.gov/study/NCT05872295) designed to evaluate the safety and tolerability of increasing dose levels of IKS014 and establish a recommended phase 2 dose. Preliminary data from this study has demonstrated promising clinical activity across multiple tumour types, including breast, ovarian, gallbladder, and oesophageal cancers, and including patients who have relapsed after prior treatment with Enhertu. Gaining access to U.S. centres for the dose expansion stage of this phase 1 trial will enable efficient confirmation of the role of IKS014 in this important patient sub-set.
Dr Dave Simpson, Chief Executive Officer, Iksuda Therapeutics, said:
'The FDA clearance of our IND application for IKS014 represents a significant milestone in our mission to address the critical unmet needs of patients with HER2-positive cancers, particularly those who have exhausted current standard-of-care options. Early clinical data has been extremely encouraging, and we are excited to expand our program to reach more patients.
'The early efficacy signals that have been observed, particularly in patients that have relapsed after receiving prior treatments of Kadcyla and Enhertu, suggest IKS014 could potentially offer a new treatment option for patients who currently have limited alternatives. We look forward to working with our clinical partners to further evaluate the potential of IKS014.'
The first stage of this phase 1 trial, to determine the recommended phase 2 dose for dose expansion, is nearing completion. The expansion phase will assess several patient cohorts including those with HER2-positive breast cancer who are refractory to or cannot tolerate Enhertu, patients with HER2-low breast cancer and patients with HER2-positive positive gastric cancer. The IND clearance will allow Iksuda to access patients across sites in the United States, alongside sites in Australia, New Zealand, and Singapore. The phase 1 trial is expected to complete in 2H 2026.
About IKS014
IKS014 is a potential best-in-class antibody drug conjugate, benefiting from tumour selective activation and release of the cytotoxic agent monomethyl auristatin F (MMAF). In preclinical trials, it displayed impressive activity in high- and low-HER2 expressing tumours with a favourable Therapeutic Index vs other HER2-directed drugs. Iksuda gained exclusive world-wide rights (excluding Greater China and South Korea) to IKS014 from LigaChem Biosciences (https://iksuda.com/2022/01/iksuda-deepens-clinical-pipeline/).
About Iksuda Therapeutics: www.iksuda.com
Iksuda Therapeutics is a clinical stage, UK-based biotechnology company focussed on the development of class leading antibody drug conjugates (ADCs) targeting difficult-to-treat haematological and solid tumours. Iksuda's pipeline of ADCs is centred on a portfolio of prodrug DNA and protein alkylating payloads in combination with stable conjugation chemistries including its proprietary PermaLink ® platform. The Company's design concepts for ADCs are now clinically validated to significantly improve the therapeutic index of this important modality and improve the outcomes for patients living with cancer.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
3 hours ago
- Fox News
Orange juice sugar cuts proposed by FDA to help citrus growers: What it means for you
The U.S. Food and Drug Administration (FDA) is proposing an update to a decades-old orange juice rule that could give American citrus growers a boost — with little to no change in the taste of the popular breakfast staple, experts say. For the first time since 1963, the agency wants to lower the minimum sugar content required in pasteurized orange juice. The proposal, announced on Aug. 6, would drop the required Brix level — a measure of dissolved solids, mostly natural sugars — from 10.5% to 10%. The shift aligns with the natural Brix levels now present in American oranges and corresponds to about 1 gram less of sugar per 8-ounce serving, from 18 grams to 17 grams, per the FDA. The change stems from a 2022 petition by the Florida Citrus Processors Association and Florida Citrus Mutual in which they said the average Brix level of Florida oranges was 9.7 in 2022–23. The current standard was established in 1963 when Florida oranges averaged 11.8 Brix. Severe weather and citrus greening disease have lowered Brix levels in fruit, forcing producers to import sweeter juice – often from Mexico and Brazil – to blend with theirs in order to meet federal standards, according to the FDA. "For years, we've been wasting beautiful American oranges simply due to an outdated regulation, while relying on a high volume of imports," FDA Commissioner Marty Makary said in a statement. The change would reduce dependency on imports, potentially saving orange producers more than $50 million annually, the agency estimated. Growers could still make higher Brix juice if supplies allow, according to the FDA. Uncle Matt's Organic, which makes a variety of juices, lemonades and iced teas, will not be lowering its Brix levels, co-founder Susan McLean said. "Uncle Matt's Organic orange juice contains no added sugar," she told Fox News Digital. "The naturally occurring sugar content comes directly from the fruit itself, and our Brix is consistently above 11.8, which is well above the minimum threshold." But the Florida-based company supports the FDA's proposal. "The update will allow struggling growers to market their fruit more effectively without compromising transparency or food safety," McLean said. The move is part of the FDA's review of over 250 Standards of Identity (SOIs), federally defined rules that spell out what certain foods must contain, and sometimes how they are made, in order to be marketed under a specific name. "The agency is working to ensure its rules are science-based, relevant and responsive to today's food supply and consumer needs," the FDA said in a statement. A public comment period on the proposed rule is open until Nov. 4. The FDA is also seeking feedback on whether to lower the Brix level further. Shannon Shepp, executive director of the Florida Department of Citrus, which has long supported the Brix adjustment, said the industry is not advocating for eliminating standards. "We support science-based updates that reflect current growing conditions, while protecting Florida oranges, our growers and the future of Florida orange juice," Shepp told Fox News Digital. "These standards are created in a spirit of honesty, so that consumers know exactly what they are getting from properly labeled products." Bryan Quoc Le, a California food scientist and author of the book "150 Food Science Questions Answered," told Fox News Digital the change in sugar content will not greatly alter the overall composition of the orange juice. For more Lifestyle articles, visit "There may be very minor changes in flavor profile, fiber content and other components that come along with orange juice, but ultimately this will not be particularly noticeable from either a health or an industry standpoint," he added. The public health impact would be minimal, agreed Dr. Michael Ednie, a Florida-based doctor who is also a registered dietitian. "Orange juice has been criticized for its sugar content because drinking lots of sugary beverages – including fruit juices – can increase risks of health problems, like diabetes and tooth decay," Ednie told Fox News Digital. Nutrition guidelines already recommend drinking fruit juice in moderation, he noted. "So, the main message for public health stays the same: Orange juice is best enjoyed in reasonable amounts as part of a balanced diet." Fox News Digital reached out to the FDA for comment.
Yahoo
6 hours ago
- Yahoo
TMO Receives FDA Approval for Oncomine Dx Target Test
Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration ('FDA') for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS (zongertinib tablets), a tyrosine kinase inhibitor (TKI). The HERNEXEOS, developed by Boehringer Ingelheim, is the first and only FDA-approved orally administered targeted therapy for adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC). The recent approval is expected to bolster Thermo Fisher's Specialty Diagnostics arm. About TMO's Oncomine Dx Target Test The Oncomine Dx Target Test checks if NSCLC tumors harbor human epidermal growth factor receptor 2 (HER2/ERBB2) tyrosine kinase domain (TKD) activating mutations. It enables multi-biomarker analysis from a single tissue sample to aid treatment decisions in as little as four days. This reduces the need for second biopsies and avoids suboptimal therapy selection in the absence of a complete biomarker report. The test is fully reimbursed by Medicare, as well as by the top 20 commercial payers in the United States. Oncomine Dx Target Test's Global Approvals The Oncomine Dx Target Test received its first approval by the FDA as an NGS CDx in 2017, followed by regulatory approvals in 20 countries for 11 biomarkers and over 20 targeted therapies. The test is reimbursed by government and commercial insurers in the United States, Europe, Japan, South Korea and Israel, covering more than 550 million lives globally. In the United States alone, it is approved for targeted therapies in NSCLC, cholangiocarcinoma (CC), astrocytoma (AC) and oligodendroglioma (OG), anaplastic thyroid cancer (ATC), medullary thyroid cancer (MTC) and thyroid cancer (TC). Industry Prospects Favor TMO According to the American Cancer Society, lung cancer is the second most common cancer in both men and women in the United States, with NSCLC accounting for about 85-90% of all lung cancer cases. Research further indicates that roughly 2-4% of NSCLC patients carry a HER2 mutation. With lung cancer cases continuing to rise, the global market for NSCLC treatments is expected to expand significantly, reaching $66.04 billion by 2032 at a CAGR of 10.3% from 2024 to 2032 (per Fortune Business Insights). Another Development by TMO Thermo Fisher recently announced the FDA approval for Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay for use as a companion diagnostic (CDx) for Dizal's ZEGFROVY (sunvozertinib) and in tumor profiling. Offerings by TMO's Competitors In the oncology space, Thermo Fisher faces competition from some prominent MedTech players. These companies are also making notable developments in their respective businesses. An expanding NGS oncology portfolio is helping Illumina ILMN drive the revolution in cancer genomics. The company's market-leading TruSight Oncology assay, TSO 500, continues to see increased utilization and broader adoption. In February, the company announced a new single-cell offering for CRISPR research with applications in oncology, immunology and drug target discovery. In 2024, the FDA approved its in vitro diagnostic (IVD) TSO Comprehensive test and its first two companion diagnostic (CDx) indications to rapidly match patients to targeted therapies. This year, Illumina is set to roll out TSO 500 v2, a new version that includes hundreds of genes across all variant classes and immuno-oncology biomarkers in a single assay from one sample, to facilitate therapy selection research. A rapidly expanding liquid biopsy and NGS-based testing portfolio is positioning Guardant Health GH as a leader in precision oncology. The company's flagship Guardant360 test has been recently enhanced with the Guardant Infinity platform, enabling a single blood draw to provide comprehensive tumor profiling, confirm the absence of actionable mutations and determine ER/PR/HER2 status. Regulatory milestones include approvals for Guardant360 CDx as a companion diagnostic in the United States, Japan and Singapore, covering multiple cancer targets such as EGFR and HER2 mutations. Its pipeline also includes the FDA-approved Shield blood test for colorectal cancer screening, offering a non-invasive alternative to colonoscopy. Exact Sciences' EXAS flagship screening product, the Cologuard test, is a non-invasive, stool-based DNA (sDNA) screening test that utilizes a multitarget approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company's precision oncology portfolio also offers the Oncotype DX Breast Recurrence Score test to identify patients who are most likely to benefit from chemotherapy, as well as those who may receive no clinical benefit from chemotherapy. Its Oncotype DX Colon Recurrence Score test is a multi-gene test for predicting recurrence risk in patients with stage II and stage III A/B colon cancer to enable an individualized approach to treatment planning. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report Illumina, Inc. (ILMN) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report Guardant Health, Inc. (GH) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Epoch Times
7 hours ago
- Epoch Times
FDA Advises Americans Against ‘Mousse' Sunscreens, Warns 5 Manufacturers
Americans should 'beware' of sunscreen products in mousse form as they may not be effective, the Food and Drug Administration (FDA) said in an Aug. 12 X post, with the agency sending warning letters to five companies marketing sunscreen products. The letters were sent on Aug. 6 to Texas-based Supergoop, Pennsylvania-based Fallien Cosmeceuticals Ltd., Israel-based K & Care Organics, Sweden-based Kalani AB, and Florida-based Vacation Inc.
